Rheumatology Healthcare Commercialization

Rheumatology care faces cost control pressures, but universally accepted patient outcome measures do not exist. Touchpoint can help your customers strike a balance between treatment efficacy and cost control.

Disease-modifying antirheumatic drugs (DMARDs) are the preferred treatment for rheumatologic and musculoskeletal diseases (RMDs). Nevertheless, patient access to these medications remains limited due to several significant barriers, including cost and prescriber comfort. Overcoming the cost barrier requires thorough documentation of patient outcomes, which in the case of rheumatology care is complicated by the lack of universally accepted objective outcome measures. However, documenting patient reported outcomes can be a viable alternative for documenting treatment outcomes to payers.

To deliver care at acceptable cost while at the same time maximizing patient outcomes, physicians treating patients with RMDs need assistance in several key areas:

  • Education on RMDs for primary care providers
  • Education on efficacy and dosing of DMARDs, including cost saving dose reductions for patients in remission
  • Differentiation of safety, efficacy, and costs between biologic and biosimilar DMARDs
  • Guidance on how to engage patients in the management of their disease, increase treatment adherence, and enable improved patient outcomes

To help rheumatologists deliver high-quality care at acceptable costs while the same time optimizing patient outcomes, Touchpoint offers expert healthcare commercialization services and teams.

Physician and patient education through our medical science liaisons and clinical health educators.

Healthcare commercialization aimed at maintaining the economic viability of rheumatology care through field-based medical sales representatives as well as inside medical sales representatives.

See how we can help your customers deliver state-of-the-art care at an acceptable cost

Contact Us